Dade launches thrombin activity test for research use:
This article was originally published in Clinica
Dade Behring believes it has moved a step closer to providing physicians with a new assay that could allow doctors to better assess thrombotic and bleeding risk. The Deerfield, Illinois firm has made available for research studies, its endogenous thrombin potential (ETP) test for measuring thrombin activity. The assay is based on the assumption that thrombin generation in plasma or whole blood reflects the sum of the activities and concentrations of procoagulant and anticoagulant substances, said the company. "ETP has the potential to become a standard parameter in coagulation, and we are confident that the research studies will provide the necessary information to bring the assay to full commercialisation," added Jim Reid-Anderson, Dade's chairman, president and CEO.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.